Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players’ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Carcinoid Syndrome Management Market Size

ID: MRFR//2100-HCR | 85 Pages | Author: Rahul Gotadki| May 2024

Cancer stands as the primary and second most significant contributor to global mortality. This disease is characterized by irregular cellular and stromal proliferation, compromised cell death, growth factor deprivation, and various other factors. At the molecular level, cancer manifests as a genetic disorder arising from gene mutations in somatic cells. The resulting phenotype exhibits genomic instability and chromosomal aneuploidy, facilitating the acceleration of genetic changes. Cellular and molecular genetic alterations, along with host-tumor interactions, play a pivotal role in tumor development and progression. Extensive research has focused on unraveling these complexities, with molecular oncology emerging as a key discipline. Molecular oncology not only enhances our understanding of cancer pathogenesis and drug mechanisms but also contributes to the development of more effective diagnostic and therapeutic strategies, encompassing both prevention and metastasis treatment.
The advent of the human genome sequence, coupled with genomic and proteomic approaches, has provided an abundance of tools and resources. However, the challenge lies in making biological sense of this vast information, constructing relevant models and hypotheses, and translating findings for clinical applications, ultimately benefiting patients.

Biological therapy, a cornerstone in cancer treatment, involves using living organisms, components of living organisms, or laboratory-manufactured versions thereof. While many biological therapies, often referred to as biological response modifiers or immunotherapy, leverage bacteria or vaccines to stimulate the body's immune system against cancer cells, others, like DNA or RNA, directly target cancer cells. Additionally, certain biological therapies inhibit specific molecules crucial for tumor development, known as cancer-targeted therapies.

This research report delves into an in-depth analysis of various cancer biological therapies globally, covering North America, Europe, Asia Pacific, the Middle East, and Africa. It provides insights into end-users and country-level analyses. The global market for cancer biological therapies, valued at $56,036 million in 2016, is anticipated to reach $82,276.8 million by 2023, exhibiting a compound annual growth rate (CAGR) of 4.7% during the forecast period.

Numerous approved biological therapies are actively employed by cancer specialists worldwide. However, ongoing research and development activities are paving the way for novel therapies, drugs, and treatments that are yet to be commercially available. The dynamic landscape of cancer biological therapies reflects continuous advancements and a commitment to addressing the complexities of cancer at the molecular and cellular levels, ultimately enhancing patient outcomes.



Covered Aspects:

Report Attribute/Metric Details

Synopsis of Carcinoid Syndrome Management Market:


Market Scenario:


The carcinoid syndrome management market is expected to reach USD 4,873.9 Million by 2030 at 10.3% CAGR during the forecast period 2022-2030.Carcinoid syndrome comprises of signs and symptoms including flushing of the face, debilitating diarrhea, asthma caused due to vasoconstriction, intestinal bleeding, fast heartbeat, shortness of breath, sweating, unexplained weight gain etc. which are settled secondary to carcinoid tumor. The management or treatment of carcinoid syndrome often requires palliative and supportive care. Management of carcinoid syndrome involves drug therapy or surgical removal of carcinoid tumor from the organ.


Increasing incidence of hormonal disorders, growing smoking habits, levels of carcinogen in highly developed countries etc. are the major driving factor, driving the growth of the market. The only factor restraining the growth of carcinoid syndrome management market is that no availability of drugs approved to manage carcinoid syndrome.


Study objectives:



  • To provide detail analysis of parent market and the changing market dynamics of the industry.

  • To provide detail analysis of the market structure along with estimated future growth forecast about various segments and sub-segments of the carcinoid syndrome management market.

  • To provide in depth market segmentation and historical, current and projected market size in terms of value and volume with respect to four main geographies and their countries- Americas, Europe, Asia-Pacific, and Middle East & Africa.

  • To provide country level analysis of the market with respect to the current market size and future growth prospect.

  • To provide detailed analysis on recent industry trends and developments, strategies of key players and competitive landscape of the Carcinoid Syndrome Management Market.

  • To track and analyze developments which are competitive in nature such as joint ventures, strategic alliances, mergers and acquisitions, new product developments along with research and developments currently taking place  in the Carcinoid Syndrome Management Market.


Figure 1           Carcinoid Syndrome Management Market by Organs Affected Carcinoid Syndrome Management Market


Key players of Carcinoid Syndrome Management Market:


Key players profiled in the Carcinoid Syndrome Management Market are Novartis International AG (Sandoz) (Switzerland), Pharmascience Inc. (Canada), Omega Laboratories Ltd. (Canada), Teva Pharmaceutical Industries Ltd. (Israel), Mylan N.V. (USA), Ipsen Biopharmaceuticals, Inc.(US), Sirtex Medical Limited (Australia) , BTG International Ltd. (UK), Wockhardt Ltd. , and  Sun Pharmaceutical Industries Limited (India),


Segments:


The carcinoid syndrome management market is segmented on the basis of organs affected by the disease, treatment procedures and end users. Based on organs affected by the disease, the market has been segmented into small intestine, lungs, rectum, appendix, colon, stomach, pancreas, liver and others. Based on treatment type, the market has been segmented into chemotherapy, biological therapy, and hepatic artery embolization agents. Further on the basis of end users the market has been segmented as hospital, clinics, and cancer institute and treatment centers. The report for Carcinoid Syndrome Management by Market Research Future comprises of extensive primary research along with the detail analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain a deeper insight of the market and industry performance. The report gives a clear picture of current market scenario which includes past and estimated future market size with respect to value and volume, technological advancement, macro economical and governing factors in the market. The report provides detail information about and strategies used by top key players in the industry. The report also gives a broad study of the different market segments and regions.Intended Audience



  • Global carcinoid syndrome management or treatment device manufacturers & suppliers

  • Contract research organizations (CROs)

  • Research and development (R&D) companies

  • Government research laboratories

  • Independent research laboratories

  • Government and independent regulatory authorities

  • Market research and consulting service providers

  • Academic institutes and universities

Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.